title: Immunophenotypic Analysis in Early Müllerian Serous Carcinogenesis.
abstract: Studies on the immunophenotypes of early forms of serous carcinoma arising from female genital tract are limited. We aimed to examine p53, p16(Ink4a), estrogen receptor (ER), progesterone receptor (PR), ERBB2, WT1, and Ki-67 protein expression in endometrial intraepithelial carcinoma (n=29), serous tubal intraepithelial lesion (n=4) and carcinoma (STIC, n=10), and the putative precursor p53 signature (n=11). Among endometrial intraepithelial carcinoma, 80% demonstrated p53 overexpression and 10% were consistent with a null phenotype. p16(Ink4a) immunostaining were observed in all endometrial intraepithelial carcinoma cases. ER, PR, ERBB2, and WT1 were positive in 54%, 25%, 11%, and 18% of cases, respectively. STIC cases demonstrated p53 overexpression and null phenotype in 90% and 10%, respectively. All STIC cases were p16(Ink4a) and WT1 positive, whereas ER and PR were positive in 70% and 20%, respectively. All STICs were negative for ERBB2. Among serous tubal intraepithelial lesion cases, 75% demonstrated p53 overexpression and 25% a null phenotype. p53 was positive in all 11 p53 signature cases, whereas p16(Ink4a) was universally negative. Finally, ER and PR were positive in 100% and 73% of p53 signature cases, respectively. These results suggest that p16(Ink4a) has a role in early Müllerian serous carcinogenesis but is absent in the earliest noncommitted lesion. p16(Ink4a) immunohistochemistry can be used as an adjunct confirmatory tool in p53-null cases with limited surface area.
authors.affiliation: Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
authors.forename: Houman
authors.initials: H
authors.lastname: Nafisi
authors.forename: Zeina
authors.initials: Z
authors.lastname: Ghorab
authors.forename: Nadia
authors.initials: N
authors.lastname: Ismill
authors.forename: Valerie
authors.initials: V
authors.lastname: Dubé
authors.forename: Anna
authors.initials: A
authors.lastname: Plotkin
authors.forename: Guangming
authors.initials: G
authors.lastname: Han
authors.forename: Matthew
authors.initials: M
authors.lastname: Cesari
authors.forename: Fang-I
authors.initials: FI
authors.lastname: Lu
authors.forename: Reda
authors.initials: R
authors.lastname: Saad
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Khalifa
authors.forename: Sharon
authors.initials: S
authors.lastname: Nofech-Mozes
mesh_terms: D063646:Carcinogenesis / Q000473:pathology; D002278:Carcinoma in Situ / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis; D018284:Cystadenocarcinoma, Serous / Q000145:classification* / Q000473:pathology; D016889:Endometrial Neoplasms / Q000473:pathology; D005185:Fallopian Tube Neoplasms / Q000473:pathology; D005260:Female; D005833:Genital Neoplasms, Female / Q000145:classification* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D010051:Ovarian Neoplasms / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D025721:WT1 Proteins / Q000032:analysis
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; D025721:WT1 Proteins; C583751:WT1 protein, human; C508053:ERBB2 protein, human